Best Peerspectives Podcasts (2025)

1
Game-Changers and Paradigm Shifts: ASCO 2025 Data Shake Up Breast Cancer Care 10:37

Play Pause

1d ago10:37

10:37

From a “game-changer” in triple-negative disease to broader paradigm shifts and practice changes, the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting was pivotal for breast cancer care, says Sara M. Tolaney, MD, MPH, chief of the Division of Breast Medical Oncology at the Dana-Farber Cancer Institute in Boston, Massachusetts. Dr. T…

1
Practice-Changing Data in Colorectal Cancer Lead to Broader Questions in Oncology 10:37

5d ago10:37

10:37

Results from the phase 3 ATOMIC trial are practice changing for colorectal cancer care and raise broader questions about immunotherapy use in patients with mismatch repair deficiencies across tumor types. Frank A. Sinicrope, MD, a professor of oncology and medicine at the Mayo Clinic Comprehensive Cancer Center in Rochester, Minnesota, presented th…

1
Oncologist Faculty Burnout Caused by “Unrealistic” Expectations, Says ASCO CEO 9:29

7d ago9:29

9:29

“An increasingly unrealistic set of performance expectations” is putting a strain on oncologist faculty members, says Clifford Hudis, MD, CEO of the American Society of Clinical Oncology (ASCO). He discussed the mounting challenges for academic cancer physicians and how ASCO is working to address them with Robert A. Figlin, MD, the interim director…

1
After Years of Inactivity, “Dizzying” Changes Hit Bladder Cancer Care 12:23

9d ago12:23

12:23

“For the first 15 years of my career, we had nothing new” in bladder cancer care, said Jonathan E. Rosenberg, MD, chief of the genitourinary oncology service at Memorial Sloan Kettering Cancer Center in New York City. Now, “the pace of change has been dizzying,” he told Robert A. Figlin, MD, the interim director of Cedars-Sinai Cancer in Los Angele…

1
Practice Changing or “Practice Confounding”? Pivotal Breast Cancer Data Raise Big Questions 12:28

13d ago12:28

12:28

Findings from the SERENA-6 trial, which examined switching therapies in patients with breast cancer ahead of disease progression, made headlines during the 2025 American Society of Clinical Oncology Annual Meeting. However, big questions remain. “I don’t know for sure if the approach is practice changing yet. I think the approach is practice confou…

1
NCCN CEO Discusses Guideline Updates, Other Key Initiatives 12:22

14d ago12:22

12:22

From digitizing its guidelines to potential embedding them in EMRs, the National Comprehensive Cancer Network (NCCN) is working to “make the workflow easier and better” for oncologists, Crystal S. Denlinger, MD, FACP, CEO of the NCCN, told Robert A. Figlin, MD, the interim director of Cedars-Sinai Cancer in Los Angeles and Steven Spielberg Family C…

1
Former National Cancer Institute Director Discusses the Future of Cancer Care 13:08

22d ago13:08

13:08

“Is it time to do something big and different? That’s always a good question to ask,” said W. Kimryn Rathmell, MD, PhD, MMHC, the immediate former director of the National Cancer Institute (NCI) and the current CEO of The Ohio State University Comprehensive Cancer Center–James Cancer Hospital and Solove Research Institute. At the 2025 American Soci…

1
Game-Changing Blood Cancer News at ASCO 2025: Rusfertide Shows Strong Benefit in Polycythemia Vera 6:41

25d ago6:41

6:41

A late-breaking abstract presented at the 2025 American Society of Clinical Oncology Annual Meeting (LBA3) showed that rusfertide significantly increased hematocrit control and improved symptoms for patients with polycythemia vera, a chronic leukemia. “We thought if we could use our understanding of iron regulation, then we could change the game a …

1
Getting Americans to Support Cancer Research May Take a New Message, Oncology Leader Says 11:40

27d ago11:40

11:40

When it comes to building support for cancer research in the current environment, “the message that we have had in our field is a good one. But we may need to craft a better message,” says Robert A. Winn, MD, director and Lipman Chair in Oncology at the Virginia Commonwealth University Massey Cancer Center in Richmond. Dr. Winn lays out a strategy …

1
“Important Milestone”: Perioperative Durvalumab Improves Event-Free Survival in Gastric Cancer 9:42

28d ago9:42

9:42

The addition of perioperative durvalumab in gastric and gastroesophageal junction cancer improved event-free survival, according to findings from the MATTERHORN study. “This trial will be an important milestone,” said Yelena Y. Janjigian, MD, chief of the Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center in New York City, …

1
What Does the Biggest News in Breast Cancer From ASCO 2025 Mean for Practice Right Now? 12:32

1M ago12:32

12:32

Data from the SERENA-6 trial, presented at the 2025 American Society of Clinical Oncology Annual Meeting, have the potential to dramatically change advanced estrogen receptor–positive, HER2-negative breast cancer care, says William J Gradishar, MD, the Betsy Bramsen Professor of Breast Oncology at Northwestern University Feinberg School of Medicine…

1
Practice-Changing “Inflection Point” Coming in ESR1-Positive Breast Cancer Care? 9:37

2M ago9:37

9:37

Editor’s Note: This interview was recorded shortly before the 2025 American Society of Clinical Oncology Annual Meeting. Big questions associated with ESR1 mutations in patients with hormone receptor–positive breast cancer may soon have answers. New data are “going to take the whole breast oncology field from one place and put it in a different pla…

1
When ESR1 Mutations Arise in Breast Cancer Patients With PIK3CA Mutations: What Next? 10:15

2M ago10:15

10:15

The approach to ESR1 and PIK3CA mutations in patients with hormone receptor–positive metastatic breast cancer continues to evolve. What role does circulating tumor DNA (ctDNA) play in treatment decisions? How should oncologists best approach patients with PIK3CA mutations who subsequently develop ESR1 mutations? VK Gadi, MD, PhD, professor and dire…

1
How “Remarkable Change” in EGFR-Mutated NSCLC Care Is Making a Difference for Patients 12:30

3M ago12:30

12:30

The last few years have seen “a remarkable change in both our approach and management of EGFR lung cancer,” says Shirish M. Gadgeel, MD, division head for hematology/oncology and associate director of Patient Experience and Clinical Care at the Henry Ford Cancer Institute in Detroit. He discusses key considerations for managing EGFR-mutated non-sma…

1
Oncologists Urged to Discuss Fertility With Patients, as ASCO Updates Guidelines 10:24

3M ago10:24

10:24

When it comes to tackling fertility issues associated with cancer, “oncology clinicians are often reluctant to talk about this because it is really not our wheelhouse,” says Alison Wakoff Loren, MD, MSCE, chief of the Division of Hematology Oncology, director of Blood and Bone Marrow Transplantation, and the C. Willard Robinson Professor of Hematol…

1
“Second-Line ER-Positive Breast Cancer Has Just Become Very Complicated” 14:40

3M ago14:40

14:40

“Second-line [estrogen receptor (ER)]-positive breast cancer has just become very complicated,” says Erika P. Hamilton, MD, the director of breast cancer and gynecologic cancer research at Sarah Cannon Research Institute in Nashville. She discusses the role of ESR1 mutations in selecting appropriate treatments and combination regimens for patients …

1
Will Generational Divide Among Oncologists Affect How AI Changes Cancer Care? 14:35

3M ago14:35

14:35

Burnout among oncologists is a serious concern, and artificial intelligence (AI) represents a potential solution, says Debra Patt, MD, PhD, MBA, a practicing oncologist and breast cancer specialist in Austin, Texas, who also serves as the chair of the AI task force for the American Society of Clinical Oncology. Technological advances are poised to …

1
“Time to Move On”: How Targeted Therapies Are Transforming AML Care 10:26

4M ago10:26

10:26

The standard approach of “7 + 3” chemotherapy in acute myeloid leukemia (AML) treatment has been in place for 50 years. But that may soon change, says Maximilian Stahl, MD, a member of the Adult Leukemia Group at the Dana-Farber Cancer Institute in Boston and a member of the faculty at Harvard University. “My prediction is that in 10 years, you wil…

1
ASCO President Speaks Out on “Huge Problem” of Oncologist Burnout 14:51

5M ago14:51

14:51

Oncologist burnout and career dissatisfaction are a “huge problem,” says Robin T. Zon, MD, president of the American Society of Clinical Oncology (ASCO). Dr. Zon sits down with Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles, to discuss revelations from a recent ASCO re…

1
Oncologists Overtreat Patients at End of Life 10:45

6M ago10:45

10:45

When it comes to end-of-life care for patients with cancer, “I think that there is a real deficit in our training,” says Nathan I. Cherny, MD, director of the Cancer Pain and Palliative Medicine Service at Shaare Zedek Medical Center in Jerusalem, Israel. Dr. Cherney and colleagues recently examined factors contributing to oncologists overtreating …

1
FDA Approvals Change Practice for Metastatic Breast Cancer With PIK3CA Mutations 11:01

7M ago11:01

11:01

Recent advances in hormone receptor–positive, HER2-negative metastatic breast cancer have led to questions about the timing of genetic testing and the optimal treatment choices for patients. “I, like many others, have changed my personal practice,” says Azka Ali, MD, a medical oncologist at the Cleveland Clinic Taussig Cancer Institute in Ohio. She…

1
To Help Oncologists’ Burnout, Should Primary Care Take on More Burden? 11:18

8M ago11:18

11:18

The European Society for Medical Oncology (ESMO) Resilience Task Force recently released recommendations intended to reduce burnout in oncology worldwide. One of the task force’s members, Konstantinos Kamposioras, MD, PhD, a consultant in medical oncology at the Christie NHS Foundation Trust in Manchester in the United Kingdom, explains to Robert A…

1
Choosing Between an “Old Friend” and New Ones in EGFR-Mutated Metastatic NSCLC 12:50

8M ago12:50

12:50

When it comes to the treatment of EGFR-mutated metastatic non-small cell lung cancer (NSCLC), osimertinib (Tagrisso) is an “old friend,” says Kamya Sankar, MD, assistant professor and co–medical director of the Thoracic Disease Research Group at Cedars-Sinai Cancer Center in Los Angeles. Recent approvals by the U.S. Food and Drug Administration hav…

1
Privatization of Cancer Clinical Research Raises Concerns for Practice 13:09

8M ago13:09

13:09

“Cancer clinical research has been largely privatized,” explains Joseph Unger, PhD, MS, associate professor in the cancer prevention program at the Fred Hutchinson Cancer Center in Seattle. Dr. Unger and colleagues recently assessed patient enrollment in industry-sponsored and federally sponsored clinical trials. They found an 8:1 ratio favoring pa…

1
What 3 Big Trials Mean for Breast Cancer Practice 12:48

9M ago12:48

12:48

Treatment approaches for patients with hormone receptor (HR)-positive, HER2-negative breast cancer have rapidly evolved, thanks in part to data from three key studies. Erin Frances Cobain, MD, associate professor at the University of Michigan Rogel Cancer Center in Ann Arbor, explains how findings from the KEYNOTE-756, monarchE, and NATALEE clinica…

1
“Confusing for All of Us”: Questions Arise Over ADCs, HER2 in Metastatic Breast Cancer 14:02

9M ago14:02

14:02

Approvals of antibody-drug conjugates (ADCs) for metastatic breast cancer have introduced complex questions about HER2 expression. “It’s certainly been a changing landscape, which has been confusing for all of us,” explains Ian Krop, MD, PhD, director of the clinical trials office, chief clinical research officer, and associate director for clinica…

1
”Where Do We Go From Here?” Targeted Therapies Lead to Challenging Choices in Breast Cancer 11:00

10M ago11:00

11:00

Newly approved targeted therapies for patients with advanced hormone receptor (HR)-positive, HER2-negative breast cancer are changing care. “We have an abundance of opportunities, but challenges with having to choose the right opportunity at the right time,” says Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the …

1
After Practice Change in Unresectable Stage III NSCLC, Questions Remain 10:30

11M ago10:30

10:30

Data on the use of durvalumab after chemoradiotherapy transformed the standard of care for patients with unresectable stage III non-small cell lung cancer (NSCLC). “This is a real practice-changing observation from the PACIFIC trial,” said Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Cent…

1
What ”Incredibly Dramatic” Data on Osimertinib in NSCLC Mean for Practice 9:47

11M ago9:47

9:47

Results of the phase 3 LAURA clinical trial, presented at the 2024 American Society of Clinical Oncology Annual Meeting, showed that osimertinib significantly improves progression-free survival in patients with unresectable stage III EGFR-mutant non-small cell lung cancer (NSCLC) after chemoradiotherapy. “The benefits of osimertinib in this patient…

1
“Smart Bombs” Upend Breast Cancer Care: What Oncologists May Not Know About Antibody-Drug Conjugates 10:08

11M ago10:08

10:08

“I think the antibody-drug conjugates (ADCs) for physicians, and certainly patients too, are a little bit tough to wrap your head around,” says Erika P. Hamilton, MD, the director of breast cancer and gynecologic cancer research at Sarah Cannon Research Institute in Nashville. She discusses how TROP2-targeting ADCs currently fit into practice with …

1
Oncology Must Do More for Long-Term Cancer Survivors, Expert Says 11:27

11M ago11:27

11:27

Various survivorship guidelines for pediatric patients have been established, but “such guidelines do not exist in the adult world,” says Smita Bhatia, MD, MPH, director of the Institute for Cancer Outcomes and Survivorship and the Gay and Bew White Endowed Professor in Pediatric Oncology at the University of Alabama at Birmingham. With the number …

1
“A Good, Peaceful Death” From Cancer: Oncologists Must Be Part of “National Dialogue” 12:00

12M ago12:00

12:00

Obstacles to “achieving a good, peaceful death” prevent many patients with cancer from the “dignified end” that they deserve, says Sunita Puri, MD, a palliative care physician and author. She and Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles, discuss frustrations and …

1
FDA Approvals in Relapsed/Refractory CLL Set up ”Difficult Choice” 9:59

12M ago9:59

9:59

When it comes to the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL), "within the last eight months or so, we have had some exciting new events," says Daniel A. Ermann, MD, a hematologist-oncologist and assistant professor at the University of Utah Huntsman Cancer Institute in Salt Lake City. The U.S. Food and Drug…

1
Oncologists Struggling With Cancer Deaths Among Millennial Patients 11:36

12M ago11:36

11:36

Oncologists are struggling with the rising cancer mortality rate among millennial patients. "I think treating people our own age is definitely a trigger for a lot of people," said Sunita Puri, MD, a palliative-care physician and author. She spoke with Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai…

1
Top Lung Cancer Data From ASCO 2024 Should Change Practice “Immediately,” Experts Agree 12:23

1y ago12:23

12:23

Thoracic oncology was a major focus of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, says Sandip P. Patel, MD, a medical oncologist and professor of medicine at the University of California San Diego. Practice-changing data were presented in both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), Dr. Patel…

1
What Were the Biggest Data at ASCO 2024 in Kidney Cancer? 11:41

1y ago11:41

11:41

The biggest data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in kidney cancer focused on biomarkers, says Brian I. Rini, MD, chief of clinical trials and the Ingram Professor of Cancer Research at the Vanderbilt-Ingram Cancer Center in Nashville. He discussed data from KEYNOTE-426 and several other key trials with Robert…

1
What New “Elephant in the Room” Means for Bladder Cancer Care 14:00

1y ago14:00

14:00

Enfortumab vedotin plus pembrolizumab (EV/pembro) has “become the elephant in the room” when it comes to bladder cancer care, says Jonathan E. Rosenberg, MD, chief of genitourinary oncology service at Memorial Sloan Kettering Cancer Center in New York City. At the 2024 American Society of Clinical Oncology Annual Meeting, he discussed recent key ad…

1
Immunotherapy in “Hardest Stage” of NSCLC: Putting Recent Advances Into Practice 12:08

1y ago12:08

12:08

Immunotherapy in “Hardest Stage” of NSCLC: Putting Recent Advances Into Practice Our host, Robert A. Figlin, MD, FACP, welcomes Melissa L. Johnson, MD, as a guestBy Oncololgy News Central

1
”We’re Past the Inflection Point,” as ”Massive Change” Hits Breast Cancer Care 13:54

1y ago13:54

13:54

From ASCO 2024. When it comes to the use of antibody-drug conjugates (ADCs) in breast cancer care, "we're past the inflection point," says Hope S. Rugo, MD, a breast cancer oncologist and professor of medicine in the Division of Hematology and Oncology at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center.…

1
To Get Better Cancer Drugs Faster, Is It Time for an “International FDA”? 13:06

1y ago13:06

13:06

From ASCO 2024 The time it takes for a novel cancer therapy to go from investigational new drug application to U.S. Food and Drug Administration (FDA) approval is typically longer than a decade. “There has to be a better way,” says Bob T. Li, MD, PhD, MPH, a medical oncologist at Memorial Sloan Kettering Cancer Center in New York City and associate…

1
”Very Important” Myeloma Data: ASCO Highlights, Smoldering Challenges, and More 12:32

1y ago12:32

12:32

From ASCO 2024, Dr. Robert Figlin speaks with Dr. Samer Al Hadadi from University of Arkansas. "Very Important" Myeloma Data: ASCO Highlights, Smoldering Challenges, and More.By Oncololgy News Central

1
Durvalumab’s Benefit in SCLC ”Beyond What We Might Have Expected” 10:29

1y ago10:29

10:29

From ASCO 2024, Dr. Robert Figlin talks with Dr. Lauren Averett Byers from MD Anderson Cancer Center. Durvalumab's Benefit in SCLC "Beyond What We Might Have Expected"By Oncololgy News Central

1
New Standard of Care in Melanoma? Neoadjuvant Immunotherapy Offers ”Fantastic” Potential, Expert Says 25:13

1y ago25:13

25:13

From ASCO 2024 New Standard of Care in Melanoma? Neoadjuvant Immunotherapy Offers "Fantastic" Potential, Expert Says. Dr. Robert Figlin speaks with Dr. Christian Blank from Leiden UniversityBy Oncololgy News Central

1
Should All Breast Cancer Patients Get T-DXd? ”Results of DESTINY-Breast06 Do Suggest That” 10:46

1y ago10:46

10:46

From ASCO 2024, Dr. Robert Figlin welcomes Dr. Aditya Bardia from UCLA Health Jonsson Comprehensive Cancer Center. Should All Breast Cancer Patients Get T-DXd? "Results of DESTINY-Breast06 Do Suggest That"By Oncololgy News Central

1
Oncologist Shortage “Has Gotten to the Crisis Level” 10:02

1y ago10:02

10:02

Especially in rural areas, the growing oncologist shortage has “gotten to crisis level,” says Harsha Vyas, MD, president and founding partner of Cancer Center of Middle Georgia in Dublin. “We just don’t have enough supply of medical oncologists/hematologists,” he tells Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology a…

1
“Monster Improvements” in CLL Care Prompt Questions About BTK Inhibitor Use 9:20

1y ago9:20

9:20

The development of noncovalent Bruton tyrosine kinase (BTK) inhibitors and other advances in chronic lymphocytic leukemia treatment signify that the “future is really exciting,” says Jennifer A. Woyach, MD, professor in the Division of Hematology at The Ohio State University in Columbus. Dr. Woyach speaks with Robert A. Figlin, MD, the Steven Spiel…

1
“Better to Have Choices”: How New Data Transform EGFR-Mutated NSCLC Care 11:01

1+ y ago11:01

11:01

Given recent data, how should oncologists choose a tyrosine kinase inhibitor (TKI) in patients with EGFR-mutated non-small cell lung cancer (NSCLC), and when should chemotherapy be introduced? “It’s better to have choices than not,” explains Paul Bunn, MD, the Dudley Chair in Cancer Research at the University of Colorado in Aurora. Dr. Bunn discuss…

1
Practice-Changing Data Introduce “Whole New Challenge” in Prostate Cancer 11:16

1+ y ago11:16

11:16

The treatment of biochemical recurrence in prostate cancer “is set for rapid development over the next few years,” says Edwin M. Posadas, MD, medical director of the Center for Uro-Oncology Research Excellence at the Samuel Oschin Comprehensive Cancer Center at Cedars-Sinai Medical Center. Data from the recent EMBARK trial have changed practice for…

1
FDA Approval for TIL Therapy “Real Milestone” That Has Been “Long Time Coming” 11:26

1+ y ago11:26

11:26

The U.S. Food and Drug Administration’s recent accelerated approval of a tumor-infiltrating lymphocyte therapy in metastatic melanoma “is a real milestone,” after the approach was “pending for decades,” explains Jeffrey S. Weber, MD, PhD, deputy director at the NYU Langone Perlmutter Cancer Center. Dr. Weber, who was part of the team to first work …

1
From “Fairytale” to Reality? Paradigm Shift in Bladder Cancer Care 10:48

1+ y ago10:48

10:48

Recent advances in metastatic urothelial carcinoma have meant that optimistic outcomes are “not as much of a fairytale,” says Robert Dreicer, MD, deputy director of the UVA Cancer Center and professor of medicine and urology at the University of Virginia School of Medicine in Charlottesville. From the recent approval of enfortumab vedotin plus pemb…